Catalent Biologics Announces Senior Leadership Appointments

January 16, 2020

Karen Flynn rejoins Catalent as president of biologics operations; regional presidents named for US and Europe.

Karen Flynn was named president of biologics and chief commercial officer Catalent, Inc. on Jan. 16, 2020 and assumes global responsibility for the company’s biologics business, including an ongoing $200-million capital investment to expand drug substance manufacturing capacity in Madison, WI and drug product fill/finish capacity in Bloomington, IN. She replaces Barry Littlejohns, who is retiring.

Flynn was named company’s executive leadership team and will report to Alessandro Maselli, Catalent’s president and chief operating officer. She has more than 30 years’ experience in commercial, operations, and general management roles within the pharmaceutical services industry; she previously worked for Cardinal Health/Catalent in various commercially focused roles. Most recently, she was senior vice-president and chief commercial officer for West Pharmaceutical Services.

In a Jan. 16, 2020 press statement announcing Flynn’s appointment, Catalent also announced other leadership changes in the biologics group.

Mike Riley, previously the vice-president/general manager of Catalent Biologics, was named region president, Biologics North America. Riley has been with Catalent for 15 years and will oversee the sites in Bloomington, Madison, Emeryville, CA, and the company’s biologics operations in Research Triangle Park, NC, and Kansas City, MO.

Manja Boerman, named region president, Biologics Europe, has more than 20 years’ experience in biotech and pharmaceutical services; she joined Catalent in December 2019 from her previous role as president of Aesica Pharmaceuticals. Boerman will oversee the company’s European biologics sites, including Brussels, Belgium and its newly acquired site in Anagni, Italy. Boerman and Riley are members of Catalent’s executive leadership team and report directly to Flynn.

Pete Buzy will continue to lead Catalent’s Gene Therapy business.

Source: Catalent